PLAY PODCASTS
493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)

493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)

The Full Ratchet (TFR): Venture Capital and Startup Investing Demystified · Nick Moran

October 6, 202539m 14s

Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover:

  • Data Science and Investment Approach
  • Investment Practices and Market Conditions
  • China's Role in Biotech and Regulatory Considerations
  • Impact of AI on Biotech and Healthcare
  • Healthcare Adoption of AI and Preventive Measures
  • Payers and Insurance Companies' Role
  • Lessons from Successful Investments
  • Generating Liquidity in a Sluggish Market
  • Future of GLP-1 Agonists

Guest Links:

The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area.

We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.

Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.